CDT Equity Business Summary

CDT Equity Inc. (NASDAQ: CDT), formerly known as Conduit Pharmaceuticals, operates as a clinical-stage specialty biopharmaceutical company utilizing an asset-light, "disease-agnostic" business model. The company generates revenue primarily through strategic licensing agreements and milestone payments by identifying and de-risking high-potential therapeutic assets—often those deprioritized by major pharma—and advancing them through Phase II trials before exiting via third-party partnerships. Its primary business segments focus on autoimmune diseases, idiopathic male infertility (IMI), oncology, and dermatology, with a pipeline led by AZD1656 (a glucokinase activator for autoimmune conditions) and AZD5904 (a myeloperoxidase inhibitor for IMI). Positioned as a lean, data-driven drug developer, CDT Equity competes directly with clinical-stage peers such as Ernexa Therapeutics, Synlogic, TNF Pharmaceuticals, and Genprex, distinguishing itself through its focus on asset repositioning and AI-driven solid-form chemistry rather than costly late-stage clinical infrastructure. The company was founded in 2019 by David Joszef Tapolczay and Dr. Freda Lewis-Hall, the latter of whom serves as Chair of the Board and brings significant pedigree as the former Chief Medical Officer of Pfizer. The leadership team is headed by CEO Dr. Andrew Regan, a veteran entrepreneur and founder of Corvus Capital, alongside Co-Founder and CFO James Bligh and Chief Scientific Officer Dr. Joanne Holland, who oversees the technical development of the firm’s intellectual property. Notable institutional backing includes Corvus Capital Ltd., which remains a major shareholder, and the company recently strengthened its financial position in early 2026 by securing a $25 million equity line of credit from institutional investors to fund its ongoing clinical programs.